Holen Sie sich die Stockscreener-App
48.09
0.72%
-0.3502
Schlusskurs vom Vortag:
$48.44
Offen:
$48.15
24-Stunden-Volumen:
2.13M
Relative Volume:
0.73
Marktkapitalisierung:
$116.81B
Einnahmen:
$43.23B
Nettoeinkommen (Verlust:
$6.79B
KGV:
12.01
EPS:
4.0051
Netto-Cashflow:
$9.17B
1W Leistung:
-3.53%
1M Leistung:
-3.16%
6M Leistung:
-3.33%
1J Leistung:
-0.70%
1-Tages-Spanne:
$47.96
$48.53
1-Wochen-Bereich:
$47.96
$49.91
52-Wochen-Spanne:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
48.09 | 117.66B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
989.19 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.17 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.90 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.36 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Benzinga
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe - Sahm
Bloom Energy-Aktie: Vorsicht geboten! - Finanztrends
Abbott-Aktie: 21 Milliarden Dollar für neues Wachstum! - Finanztrends
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm
Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends
A Technical View of the Leifras Co Ltd ADR (LFS) - fostersleader.com
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Roche Holding Stock Popped Today - Finviz
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm
UPDATE - GlobeNewswire Inc.
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail
Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):